<DOC>
	<DOCNO>NCT01542944</DOCNO>
	<brief_summary>The aim study evaluate efficacy TevaGastrim biosimilar version Filgrastim recombinant human G-CSF ( G-CSF ) mobilize sufficient number stem cell normal sibling donor allogeneic stem cell transplantation .</brief_summary>
	<brief_title>TevaGastrim Stem Cell Mobilization Sibling Donors</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Age 18 70 year . 2 . Normal sibling donor HLA match patient AML MDS need eligible allogeneic stem cell transplantation 3 . Written informed consent . 1 . Inability tolerate PBPC harvest . 2 . Peripheral venous access possible . 3 . Positive pregnancy test female donor . 4 . Positive serology hepatitis C and/or HBSAg , unless negative antigen PCR . 5 . Psychiatric , addictive , disorder compromise ability give truly informed consent participation study . 6 . Treatment investigational drug . 7 . Known sensitivity CHO derive product . 8 . HIV positive . 9 . History malignant disease current malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Stem Cell Mobilization</keyword>
	<keyword>Allogeneic Stem Cell Transplantation</keyword>
</DOC>